Novartis no longer expects earnings decline at under-review Sandoz unit

Novartis no longer expects earnings decline at under-review Sandoz unit The pharma major also said it was now targeting $1.5 billion in savings from an ongoing group-wide cost cutting scheme, where it had previously seen savings of up to $1 billion by 2024. https://ift.tt/lvaUj8X